2023
DOI: 10.51403/0868-2836/2022/926
|View full text |Cite
|
Sign up to set email alerts
|

Identification of bioactive compounds Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening

Abstract: Drug discovery and development for Mycobacterium tuberculosis (Mtb) has progressed significantly in more than 20 years, although it is still woefully underfunded. From a drug discovery perspective, tuberculosis is a particularly challenging disease. Screening for new antimicrobial agents is routinely conducted only against actively replicating bacteria. However, it is now widely accepted that a physiological state of nonreplicating persistence (NRP) is responsible for antimicrobial tolerance in many bacterial … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles